To reduce serious influenza-related illness and death, the Centers for Disease Control and Prevention now recommends that all persons aged 50 and older receive an annual flu shot. Previously, the recommendation had included annual vaccination for all persons aged 65 and older, but the CDC found that up to a third of those 50 to 64 have chronic medical conditions that put them at increased risk for flu-related complications and death.
To reduce serious influenza-related illness and death, the Centers for Disease Control and Prevention now recommends that all persons aged 50 and older receive an annual flu shot. Previously, the recommendation had included annual vaccination for all persons aged 65 and older, but the CDC found that up to a third of those 50 to 64 have chronic medical conditions that put them at increased risk for flu-related complications and death.
In addition to all persons aged 50 and older, the CDC recommends influenza vaccination of the following high-risk groups for the 2000-2001 flu season:
• Residents of nursing homes and other chronic-care facilities that house persons of any age who have chronic medical conditions.
• Adults and children who have chronic disorders of the pulmonary or cardiovascular systems, including asthma.
• Adults and children who have regular medical follow-up or hospitalization during the preceding year because of shrink metabolic diseases (including diabetes mellitus), renal dysfunction, hemoglobinopathies or immunosuppression (including immunosuppression caused by medications or by human immunodeficiency virus).
• Children and teenagers (aged six months to 18 years) who are receiving long-term aspirin therapy and therefore might be at risk for developing Reye syndrome after influenza infection.
• Women who will be in the second or third trimester of pregnancy during the influenza season.
According to the CDC, influenza causes an average of 20,000 deaths and 110,000 hospitalizations in the United States per year. PR
Novel GLP-1 Receptor Agonist Demonstrates Promising Results Treating Patients with Obesity
January 21st 2025Data from a Phase Ia single ascending dose study found that ASC30 demonstrated dose-proportional pharmacokinetics, a half-life of up to 60 hours, and superior pharmacokinetic properties compared to other oral GLP-1 receptor agonists.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
FDA Approves Amgen’s Lumakras Plus Vectibix for KRAS G12C-Mutated Metastatic Colorectal Cancer
January 20th 2025Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and Vectibix significantly improved progression-free survival in patients with KRAS G12C-mutated metastatic colorectal cancer.